Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Prolight Diagnostics ABNGM:PRLD +2.29%31 Equity-to-Asset is 0.87 as of Mar. 2026, which is 7% below its 10-year median of 0.94. GuruFocus rates NGM:PRLD with a GF Score™ of 31/100. The stock has 1 warning sign investors should review. Among 853 Medical Devices & Instruments companies, Prolight Diagnostics AB ranks better than 87.92% on this metric.
The historical rank and industry rank for Prolight Diagnostics AB's Equity-to-Asset or its related term are showing as below:
NGM:PRLD'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.72 Med: 0.94 Max: 0.99
Current: 0.87
During the past 10 years, the highest Equity to Asset Ratio of Prolight Diagnostics AB was 0.99. The lowest was 0.72. And the median was 0.94.
NGM:PRLD's Equity-to-Asset is ranked better than 87.92% of 853
companies
in the Medical Devices & Instruments industry
Industry Median: 0.64
vs NGM:PRLD: 0.87
Prolight Diagnostics AB (NGM:PRLD) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Prolight Diagnostics AB Equity-to-Asset Related Terms
Prolight Diagnostics AB Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NGM:PRLD vs ISRG, BDX, MDLN: Equity-to-Asset Comparison
For the Medical Instruments & Supplies subindustry, Prolight Diagnostics AB's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prolight Diagnostics AB Equity-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Prolight Diagnostics AB's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Prolight Diagnostics AB's Equity-to-Asset falls into.
Prolight Diagnostics AB Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Prolight Diagnostics AB's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prolight Diagnostics AB (NGM:PRLD) has a Equity-to-Asset of 0.87 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Prolight Diagnostics AB and its competitors. This is near median its historical median of 0.94. Over the past decade, Prolight Diagnostics AB's Equity-to-Asset has ranged from 0.72 to 0.99. According to the industry distribution chart, Prolight Diagnostics AB ranks #103 out of 853 companies in the Medical Devices & Instruments industry, placing it in the top 12.1%.
Is Prolight Diagnostics AB's Equity-to-Asset too high?
Prolight Diagnostics AB's current Equity-to-Asset of 0.87 is near median its 10-year median of 0.94. Over the past 10 years, this metric has ranged from a low of 0.72 to a high of 0.99. The Medical Devices & Instruments industry median Equity-to-Asset is 0.64. Prolight Diagnostics AB's value of 0.87 is 35.9% above this industry median. Based on the distribution chart, Prolight Diagnostics AB ranks #103 out of 853 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Prolight Diagnostics AB has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Prolight Diagnostics AB's Equity-to-Asset compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Prolight Diagnostics AB ranks #103 out of 853 companies for Equity-to-Asset. This places Prolight Diagnostics AB in the top 12% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.64. Prolight Diagnostics AB's value of 0.87 is 35.9% above this benchmark. Historically, Prolight Diagnostics AB's own Equity-to-Asset has ranged from 0.72 to 0.99 over the past decade. While the company's 10-year median is 0.94 vs. the industry median of 0.64, Prolight Diagnostics AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Devices & Instruments company?
The median Equity-to-Asset among Medical Devices & Instruments companies is 0.64, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Prolight Diagnostics AB's current Equity-to-Asset of 0.87 is 35.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Prolight Diagnostics AB and its competitors. For the Medical Devices & Instruments industry, the median Equity-to-Asset is 0.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prolight Diagnostics AB's current Equity-to-Asset is 0.87, which is near median its own 10-year median of 0.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prolight Diagnostics AB stock overvalued right now?
Prolight Diagnostics AB (NGM:PRLD) has a current Equity-to-Asset of 0.87. The current Equity-to-Asset is 0.87, which is near median its 10-year median of 0.94 and 35.9% above the Medical Devices & Instruments industry median of 0.64. Prolight Diagnostics AB's overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Prolight Diagnostics AB (NGM:PRLD), the current Equity-to-Asset is 0.87 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Prolight Diagnostics AB along with its subsidiaries, develops Point-of-Care (POC) systems, which are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood. Its product portfolio includes Psyros, a digital POC technology, and Microflex.
31GF Score
Get the complete analysis for NGM:PRLD
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NGM:PRLD has been successfully added to your 
